| 1.24 -0.09 (-6.77%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.53 |
1-year : | 1.69 |
| Resists | First : | 1.31 |
Second : | 1.45 |
| Pivot price | 1.29  |
|||
| Supports | First : | 1.08 |
Second : | 0.9 |
| MAs | MA(5) : | 1.29 |
MA(20) : | 1.28 |
| MA(100) : | 1.32 |
MA(250) : | 1.32 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 40.6 |
D(3) : | 45 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 1.87 | Low : | 1.01 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PMVP ] has closed above bottom band by 27.6%. Bollinger Bands are 29.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.35 - 1.36 | 1.36 - 1.37 |
| Low: | 1.21 - 1.22 | 1.22 - 1.23 |
| Close: | 1.23 - 1.24 | 1.24 - 1.25 |
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
Fri, 10 Jul 2026
ArrowMark Colorado Holdings (PMVP) holds 3.67% stake in PMV Pharmaceuticals - Stock Titan
Tue, 07 Jul 2026
PMV Pharmaceuticals outlines its cancer drug pipeline as shares trade quietly - AD HOC NEWS
Thu, 25 Jun 2026
PMVP Forecast — Price Target — Prediction for 2027 - TradingView
Wed, 24 Jun 2026
PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why - Yahoo Finance
Tue, 16 Jun 2026
PMVP Q1 2026 Earnings: Narrower-Than-Expected Loss Mitigates Stock Decline - Earnings Cycle Outlook - dars.gov.et
Wed, 10 Jun 2026
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 67.7 (%) |
| Shares Short | 2,910 (K) |
| Shares Short P.Month | 3,260 (K) |
| EPS | -1.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.64 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.2 % |
| Return on Equity (ttm) | -63.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -75 (M) |
| Levered Free Cash Flow | -47 (M) |
| PE Ratio | -0.84 |
| PEG Ratio | 0 |
| Price to Book value | 0.75 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|